Literature DB >> 8193882

The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG).

C Hürny1, J Bernhard, M Bacchi, B van Wegberg, M Tomamichel, U Spek, A Coates, M Castiglione, A Goldhirsch, H J Senn.   

Abstract

Subjective well-being is a major aspect of quality of life and is therefore increasingly used as an endpoint in clinical trials. It is influenced to a great extent by the complex process of coping with the disease and its treatment. Assessment of coping is methodologically demanding, especially in large clinical trials. We therefore developed a single-item measure, the Perceived Adjustment to Chronic Illness Scale (PACIS), as an indicator of coping, complementary to other scales related to quality of life. We sought to validate this instrument in a subgroup of 121 Swiss patients participating in the International Breast Cancer Study Group (IBCSG) adjuvant trials. At months 3 and 6 of adjuvant treatment PACIS showed a distinct pattern of highly significant rank correlations with several disease- and treatment-related problem areas from the Herschbach coping inventory (FBBK); 42% of the variance of PACIS at month 3 was explained by the FBBK (P = .0001). The portion of explained variance was considerably higher for the Italian- (70%) than for the German-speaking (30%) subgroups. Patients who rated more effort to cope with their disease on PACIS indicated more frequent use of 3 of 15 coping strategies in relation to psychological distress. These were "crying and becoming desperate", "taking tranquillizers and alcohol" and "other people are far worse off". These three coping strategies may define a high-risk group for poor psychosocial outcome. Patients whose PACIS scores showed that it required less effort to cope tended to use the strategy "seeing a positive side of the problem". We conclude that PACIS can be used as a global indicator of the coping process in large multicultural clinical trials of adjuvant therapy for breast cancer.

Entities:  

Mesh:

Year:  1993        PMID: 8193882     DOI: 10.1007/BF00366447

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  13 in total

1.  Coping and survival in patients with primary breast cancer: a critical analysis of current research strategies and proposal of a new approach integrating biomedical, psychological, and social variables.

Authors:  C Hürny; J Bernhard
Journal:  Recent Results Cancer Res       Date:  1989

Review 2.  Epidemiological studies of life change and illness.

Authors:  R H Rahe
Journal:  Int J Psychiatry Med       Date:  1975       Impact factor: 1.210

3.  [Problems and coping with problems by tumor patients in inpatient after care].

Authors:  P Herschbach; G Henrich
Journal:  Psychother Psychosom Med Psychol       Date:  1987-06

4.  Why me? Attributions and adjustment by cancer patients and their mates at two stages in the disease process.

Authors:  C C Gotay
Journal:  Soc Sci Med       Date:  1985       Impact factor: 4.634

5.  Measuring the quality of life of cancer patients: a concise QL-index for use by physicians.

Authors:  W O Spitzer; A J Dobson; J Hall; E Chesterman; J Levi; R Shepherd; R N Battista; B R Catchlove
Journal:  J Chronic Dis       Date:  1981

6.  Quality of life measures for patients receiving adjuvant therapy for breast cancer: an international trial. The International Breast Cancer Study Group.

Authors:  C Hürny; J Bernhard; R D Gelber; A Coates; M Castiglione; M Isley; D Dreher; H Peterson; A Goldhirsch; H J Senn
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

7.  The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG).

Authors:  C Hürny; J Bernhard; M Bacchi; B van Wegberg; M Tomamichel; U Spek; A Coates; M Castiglione; A Goldhirsch; H J Senn
Journal:  Support Care Cancer       Date:  1993-07       Impact factor: 3.603

8.  Psychological factors in the prognosis of malignant melanoma: a prospective study.

Authors:  G N Rogentine; D P van Kammen; B H Fox; J P Docherty; J E Rosenblatt; S C Boyd; W E Bunney
Journal:  Psychosom Med       Date:  1979-12       Impact factor: 4.312

9.  Psychosocial correlates of cancer survival: a subsequent report 3 to 8 years after cancer diagnosis.

Authors:  B R Cassileth; W P Walsh; E J Lusk
Journal:  J Clin Oncol       Date:  1988-11       Impact factor: 44.544

10.  Psychosocial correlates of survival in advanced malignant disease?

Authors:  B R Cassileth; E J Lusk; D S Miller; L L Brown; C Miller
Journal:  N Engl J Med       Date:  1985-06-13       Impact factor: 91.245

View more
  31 in total

1.  Quantitative assessment of changes in patients' constructs of quality of life: an application of multilevel models.

Authors:  Adam Lowy; Jürg Bernhard
Journal:  Qual Life Res       Date:  2004-09       Impact factor: 4.147

2.  Health related quality of life: a changing construct?

Authors:  Jürg Bernhard; Adam Lowy; Natascha Mathys; Richard Herrmann; Christoph Hürny
Journal:  Qual Life Res       Date:  2004-09       Impact factor: 4.147

3.  Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.

Authors:  Jürg Bernhard; Weixiu Luo; Karin Ribi; Marco Colleoni; Harold J Burstein; Carlo Tondini; Graziella Pinotti; Simon Spazzapan; Thomas Ruhstaller; Fabio Puglisi; Lorenzo Pavesi; Vani Parmar; Meredith M Regan; Olivia Pagani; Gini F Fleming; Prudence A Francis; Karen N Price; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Barbara A Walley
Journal:  Lancet Oncol       Date:  2015-06-16       Impact factor: 41.316

4.  Assessing health-related quality of life in patients with breast cancer: a reply to Maratia et al.

Authors:  Karin Ribi; Alan Coates; Lynette Blacher; Meredith M Regan; Richard D Gelber; Jürg Bernhard
Journal:  Qual Life Res       Date:  2017-09-05       Impact factor: 4.147

5.  Patterns over time in quality of life, coping and psychological adjustment in late stage melanoma patients: an application of multilevel models.

Authors:  J E Brown; M T King; P N Butow; S M Dunn; A S Coates
Journal:  Qual Life Res       Date:  2000-02       Impact factor: 4.147

6.  Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial.

Authors:  Diana Crivellari; Kathryn P Gray; Silvia Dellapasqua; Fabio Puglisi; Karin Ribi; Karen N Price; István Láng; Lorenzo Gianni; Simon Spazzapan; Graziella Pinotti; Jean-Marc Lüthi; Richard D Gelber; Meredith M Regan; Marco Colleoni; Monica Castiglione-Gertsch; Rudolf Maibach; Manuela Rabaglio; Alan S Coates; Aron Goldhirsch
Journal:  Breast       Date:  2013-02-28       Impact factor: 4.380

7.  The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG).

Authors:  C Hürny; J Bernhard; M Bacchi; B van Wegberg; M Tomamichel; U Spek; A Coates; M Castiglione; A Goldhirsch; H J Senn
Journal:  Support Care Cancer       Date:  1993-07       Impact factor: 3.603

8.  Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy.

Authors:  J Bernhard; D Dietrich; B Glimelius; V Hess; G Bodoky; W Scheithauer; R Herrmann
Journal:  Br J Cancer       Date:  2010-09-28       Impact factor: 7.640

9.  "Fatigue and malaise" as a quality-of-life indicator in small-cell lung cancer patients. The Swiss Group for Clinical Cancer Research (SAKK)

Authors:  C Hürny; J Bernhard; R Joss; E Schatzmann; F Cavalli; K Brunner; P Alberto; H J Senn; U Metzger
Journal:  Support Care Cancer       Date:  1993-11       Impact factor: 3.603

10.  Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

Authors:  Karin Ribi; Weixiu Luo; Jürg Bernhard; Prudence A Francis; Harold J Burstein; Eva Ciruelos; Meritxell Bellet; Lorenzo Pavesi; Ana Lluch; Marilena Visini; Vani Parmar; Carlo Tondini; Pierre Kerbrat; Antonia Perelló; Patrick Neven; Roberto Torres; Davide Lombardi; Fabio Puglisi; Per Karlsson; Thomas Ruhstaller; Marco Colleoni; Alan S Coates; Aron Goldhirsch; Karen N Price; Richard D Gelber; Meredith M Regan; Gini F Fleming
Journal:  J Clin Oncol       Date:  2016-03-28       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.